drugset
Drugs / 4H11-28z/fIL-12/EGFRt+
last change Aug 2015 re-read 8 days ago

4H11-28z/fIL-12/EGFRt+

Cell therapy targets MUC16

Developed for
cancer
Investigated by
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Memorial Sloan Kettering Cancer Center · Stanford University

Trials 1

today NCT02498912 · Ph 1
201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02498912 Aug 2015 → Aug 2027 expected cancer Memorial Sloan Kettering Cancer Center Active not recruiting No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as 4H11-28z/fIL-12/EGFRt+ ClinicalTrials.gov intervention name — accepted as the source's own label NCT02498912 ↗
Modality Cell therapy “genetically-modified T cells” NCT02498912 ↗
Route Intravenous “The IV infusion will be given first.” NCT02498912 ↗
Target MUC16 “to target the MUC16ecto antigen” NCT02498912 ↗